These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 33732313)

  • 1. Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).
    Peng X; Chen L; Chen L; Wang B; Wang Y; Zhan X
    Exp Ther Med; 2021 Apr; 21(4):340. PubMed ID: 33732313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
    Hu Y; Tian ZG; Zhang C
    Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.
    Wang L; Dou M; Ma Q; Yao R; Liu J
    Int Immunopharmacol; 2019 Sep; 74():105695. PubMed ID: 31254958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.
    Pan S; Wang F; Jiang J; Lin Z; Chen Z; Cao T; Yang L
    Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):153-162. PubMed ID: 36437159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing natural killer cells to develop next-generation cellular immunotherapy.
    Liu S; Nguyen K; Park D; Wong N; Wang A; Zhou Y
    Chronic Dis Transl Med; 2022 Dec; 8(4):245-255. PubMed ID: 36420177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
    Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
    Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
    Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
    Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
    Zhao Y; Zhou X
    Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of natural killer immunotherapy in blood cancers and solid tumors.
    Sayegh M; Ma S; Yu J
    Curr Opin Oncol; 2023 Sep; 35(5):446-452. PubMed ID: 37551952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
    Lu H; Zhao X; Li Z; Hu Y; Wang H
    Front Oncol; 2021; 11():720501. PubMed ID: 34422667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors.
    He J; Yan Y; Zhang J; Wei Z; Li H; Xing L
    Front Immunol; 2023; 14():1298683. PubMed ID: 38162672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.
    Wang X; Yang X; Yuan X; Wang W; Wang Y
    Exp Hematol Oncol; 2022 Nov; 11(1):85. PubMed ID: 36324149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor engineered natural killer cells for cancer therapy.
    Zhang Y; Zhou W; Yang J; Yang J; Wang W
    Exp Hematol Oncol; 2023 Aug; 12(1):70. PubMed ID: 37563648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.
    Baghery Saghchy Khorasani A; Yousefi AM; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109041. PubMed ID: 35839565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-Expressing Natural Killer Cells for Cancer Retargeting.
    Kloess S; Kretschmer A; Stahl L; Fricke S; Koehl U
    Transfus Med Hemother; 2019 Feb; 46(1):4-13. PubMed ID: 31244577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.
    Wang Y; Jin S; Zhuang Q; Liu N; Chen R; Adam SA; Jin J; Sun J
    MedComm (2020); 2023 Dec; 4(6):e422. PubMed ID: 38045827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
    Zhang C; Oberoi P; Oelsner S; Waldmann A; Lindner A; Tonn T; Wels WS
    Front Immunol; 2017; 8():533. PubMed ID: 28572802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.